## **Declaration of Conformity** Trinity Biotech Trade name: Trinity Biotech USA Trinity Biotech, plc. 2823 Girts Road **IDA Business Park** Authorized Jamestown, NY, USA 14701 Bray, Co. Wicklow, Ireland Manufacturer: Representative: Tel: +716 483 3851 Tel: + 353 1 276 9800 Fax: +716 488 1990 Fax: + 353 1 276 9888 This Declaration of Conformity is issued under the sole responsibility of the manufacturer, Trinity Biotech USA. Basic UDI-DI: 05391516744829 / 05391516744836 51804 GMDN Code: GMDN Term: Treponema pallidum immunoglobulin G (IgG) antibody IVD, kit, enzyme immunoassay (EIA) **Product** Captia<sup>™</sup> Syphilis (T. pallidum) IgG Name: Catalogue 800-970 / 800-960 Number: Captia™ Syphilis (T. pallidum) IgG is an enzyme immunoassay for the qualitative detection of IgG antibodies to T. pallidum in serum specimens, to be used in conjunction with non-treponemal testing to provide serological evidence of infection with T. pallidum (the agent of syphilis). Intended Purpose: Captia™ Syphilis (*T. pallidum*) IgG is also intended for testing of serum or plasma specimens to screen blood and/or plasma donors to exclude a history of syphilis. Conformity Annex III for a non-self-testing kit Assessment Route: The device covered by this declaration is in conformity with Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. References to common Not applicable specifications: Name and identification N/A number of the Notified Body: ISO13485:2016 / EN ISO 13485:2016 Assessment Procedure(s) MDSAP (Medical Device Single Audit Program) utilized to verify Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices including all applicable standards conformity: ISO 13485:2016/ EN ISO 13485:2016; Certificate 1780.181030, Issued October 30, 2018 Certificates ISO 13485:2016/ MDSAP; Certificate 1781.181030, Issued October 30, 2018 Issued: EC Certificate; Certificate N/A, Issued N/A Issuance of Declaration: Trinity Biotech agrees to develop, implement, and maintain a documented post-production monitoring process, notification of reportable events under the European Medical Device Vigilance System Guidelines. Place: Trinity Biotech USA Name: Pamela Netzel Signature: Title: **Director of Quality Systems** September 28, 2020 Date: